Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2015

To view an abstract, select an author from the vertical list on the left.

2015 Grants - Gräff

Neuronal Activity as a Trigger for Alzheimer’s Disease: A Cell Type-Specific Investigation

Johannes Gräff, Ph.D.
Ecole Polytechnique Fédérale de Lausanne (EPFL)
Lausanne, Switzerland

2015 New Investigator Research Grant

How does abnormal activity in certain nerve cells contribute to the development of Alzheimer’s disease?

Because Alzheimer’s disease is a progressive disorder, much dementia research has focused on identifying brain changes that occur in the earliest disease stages. A greater understanding of these changes could lead to the development of therapies that slow the disease’s progress before memory loss and other clinical symptoms arise. According to recent studies, certain nerve cells become excessively active early in the disease process. Such prolonged activity may damage the nerve cells and prevent them from communicating with one another, leading to problems with memory and other cognitive functions.

Johannes Gräff, Ph.D., and colleagues have developed a new genetically-engineered mouse to specifically study these types of brain changes. This mouse has been engineered to develop Alzheimer’s-like brain changes and also contain a compound that can bind to and “highlight” specific nerve cells that become abnormally active.

Research Plan
For their current studies, Dr. Gräff and colleagues will use their genetically-engineered mice to identify which types of nerve cells display excessive activity early in the disease process. They will then isolate these nerve cells to study their molecular and genetic features in detail. The researchers will also chemically “deactivate” this specific group of nerve cells, in order to determine if this “quieting” can reduce Alzheimer’s-associated brain changes and improve cognitive function.

Dr. Gräff’s effort could improve our understanding of how abnormal nerve cell activity may trigger the molecular and cellular changes that contribute to Alzheimer’s disease. These findings could also promote the development of novel strategies for diagnosing and possibly treating the disease at an early stage.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.